1 min read
BrainStorm Cell Therapeutics Posts $0.68 Q3 Loss, Misses Estimate by $0.50
Cash, cash equivalents and restricted cash totaled about $350,000 at Sept. 30, 2026, up from about $240,000 a year earlier.

BrainStorm Cell Therapeutics posted a third-quarter GAAP loss of $0.68 per share, missing the estimate by $0.50. Its cash, cash equivalents and restricted cash totaled about $350,000 at Sept. 30, 2026.
The combined cash total was about $240,000 at Sept. 30, 2025, making the 2026 balance about $110,000 higher than a year earlier.